Citius Pharmaceuticals Resubmits the Biologics License Application of Lymphir (denileukin diftitox) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-Cell Lymphoma
CRANFORD, N.J., Feb. 13, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ( " Citius " or the " Company " ) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 13, 2024 Category: Drugs & Pharmacology Source Type: news

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and…#nih #vincerx #paloalto #vincerxpharma #cdk9 #ahmedhamdy #nonhodgkin #ianflinn #phd #vip236 (Source: Reuters: Health)
Source: Reuters: Health - January 7, 2024 Category: Consumer Health News Source Type: news

PET/CT scans ‘crucial’ in patients with NK/T-cell lymphoma
PET/CT has significant advantages over conventional methods for lesion detection and staging in patients with natural killer/T-cell lymphoma, according to a study published December 18 in Heliyon.In a retrospective analysis, a team in Taiyuan, China, found that F-18 FDG-PET/CT was superior for analyzing imaging manifestations of NK/T-cell lymphoma and suggested that the scans can improve treatment plans for patients.“F-18 FDG-PET/CT scanning is crucial in identifying tumor lesions, determining staging, and devising treatment strategies for individuals diagnosed with NK/T-cell lymphoma,” wrote lead author Huixia Geng, M...
Source: AuntMinnie.com Headlines - December 22, 2023 Category: Radiology Authors: Will Morton Tags: Radiation Oncology/Therapy Source Type: news

CAR T Therapy May Cause Rare Cancer & How CRISPR Could Be The Solution
CAR T therapy safety falls into question as the FDA investigates reports of rare T cell lymphoma after treatment. This concern could be resolved with CRISPR technology. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 19, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma
(MedPage Today) -- Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings from a single-arm phase II study showed. Among... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 15, 2023 Category: Hematology Source Type: news

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published in The Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 10, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news

Lymphoid Reaction Observed in Eczema Patients Receiving Dupilumab
MONDAY, Oct. 30, 2023 -- For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study published online Oct. 18 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 30, 2023 Category: Pharmaceuticals Source Type: news

What is angioimmunoblastic T-cell lymphoma? Rare blood cancer suffered by Jurassic Park star Sam Neill, 76, affects just 5,000 Americans annually - but can kill 87% within 5 years
Sam Neill, the 76-year-old actor from New Zealand, has angioimmunoblastic T-cell lymphoma (AITL), a rare cancer affecting the lymphatic system, the body's disease-fighting network. (Source: the Mail online | Health)
Source: the Mail online | Health - October 16, 2023 Category: Consumer Health News Source Type: news

Family wonders if a quicker cancer diagnosis could have saved Thunder Bay, Ont., woman's life
A Thunder Bay, Ont., nurse who lost her mother last summer to Stage 4 T-cell lymphoma is pushing for a new policy to make it easier for patients to receive cancer diagnoses. She wants to know why a patient can't see a hematologist until the cancer is verified. Here's what we learned. (Source: CBC | Health)
Source: CBC | Health - September 25, 2023 Category: Consumer Health News Tags: News/Canada/Thunder Bay Source Type: news

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Resubmission to FDA planned for early 2024 CRANFORD, N.J., Sept. 8, 2023 -- (Healthcare Sales & Marketing Network) -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has rec... Biopharmaceuticals, Oncology, FDA Citius Pharmaceuticals, LYMPHIR, denileukin diftitox, T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2023 Category: Pharmaceuticals Source Type: news

Chlormethine Gel for the Treatment of Mycosis Fungoides Chlormethine Gel for the Treatment of Mycosis Fungoides
Review the use of chlormethine gel, a topical antineoplastic agent, for the treatment of stage IA and IB mycosis fungoides-cutaneous T-cell lymphoma.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas
(MedPage Today) -- Allogeneic hematopoietic stem cell transplantation (HSCT) was associated with significant improvements in progression-free survival (PFS) in patients with advanced cutaneous T-cell lymphomas (CTCLs), according to the propensity... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 11, 2023 Category: Dermatology Source Type: news

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 4, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ... Biopharmaceuticals, Oncology Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 4, 2023 Category: Pharmaceuticals Source Type: news

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval PRINCETON, N.J., Feb. 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2023 Category: Pharmaceuticals Source Type: news

Extracorporeal Photopheresis and Its Use in Dermatology Extracorporeal Photopheresis and Its Use in Dermatology
While cutaneous T-cell lymphoma remains the only FDA approved use of extracorporeal photopheresis, it has potential as an off-label treatment for numerous dermatological conditions.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news